Novo Nordisk Unveils New Manufacturing Facility In India

Novo Nordisk has inaugurated a new facility with a capacity of 26 million vials per annum in partnership with Torrent Pharmaceuticals.

Jesper Hoiland, senior vice president of international operations at Novo Nordisk, said: “That the company already had a manufacturing facility in China and was also looking for opportunities in countries like Bangladesh.”

He also said that India can be looked forward to developing as a hub for manufacturing insulin for neighbouring countries, and South Asia.

Hoiland added, “Currently India’s share in Novo Nordisk’s global turnover is negligible, around 1-1.5 per cent, but it is steadily growing at a rate of 20-30 per cent.”

Sanjay Dalal, chief operating officer of Torrent Pharmaceuticals, said: “Company had invested around $11m on this dedicated insulin manufacturing facility for Novo Nordisk and this could be expanded depending on market demand with slight de-bottlenecking in the coming years without the need to invest further. The Kadi facility could also be used to export insulin from India later on.”